US President Donald Trump has unveiled a phased tariff plan for imported generic medicines that could reshape the global pharmaceutical industry and pose a major challenge for Indian drug manufacturers. Under the proposed policy, imported generic medicines will continue to enjoy zero tariffs from August 1, 2026, until July 31, 2028, after which they will face a 100% tariff for one year, followed by a 200% duty from August 1, 2029.

Announcing the policy on Truth Social, Trump said the move is aimed at encouraging pharmaceutical companies to relocate manufacturing facilities to the United States and reduce America's dependence on overseas drug production.

Two-Year Window to Shift Production

The phased approach gives global pharmaceutical companies a two-year transition period to establish manufacturing operations in the US before the higher tariffs take effect.

According to Trump, companies that invest in American production facilities during this period will be better positioned to avoid the steep import duties later. He described the initiative as part of a broader strategy to strengthen domestic pharmaceutical manufacturing and improve supply chain resilience.

The policy will apply only to generic medicines, while the administration's existing approach toward patented and innovative drugs will remain unchanged.

Major Implications for Indian Pharma

The announcement is being closely watched in India, which is one of the world's largest producers of generic medicines. India supplies nearly 30% of the world's generic drugs and is a key supplier to the US healthcare system.

Indian pharmaceutical companies derive a significant share of their revenue from the American market. If the proposed tariffs are implemented as announced, exporters may face difficult choices between absorbing higher costs, shifting manufacturing to the US, or passing additional expenses on to buyers.

Industry experts believe companies with existing manufacturing facilities in the United States may gain a competitive advantage, while firms relying entirely on exports from India could face increased financial pressure.

Supply Chains May Be Reshaped

Generic medicines are manufactured through highly integrated global supply chains involving active pharmaceutical ingredients (APIs), formulations, packaging, and logistics spread across multiple countries.

The proposed tariff roadmap is expected to prompt multinational pharmaceutical companies to reassess their production networks. Establishing manufacturing units in the US would require substantial investment and several years of planning, making the two-year transition period crucial for strategic decisions.

Analysts also warn that if production shifts cannot keep pace with demand, medicine prices in the US could increase despite the administration's broader efforts to reduce healthcare costs.

Wider Trade Strategy

The latest proposal builds on the Trump administration's broader protectionist trade agenda. Earlier this year, Washington introduced tariffs on several pharmaceutical imports while temporarily exempting generic medicines and biosimilars.

The new announcement extends that strategy to generic drugs, reflecting the administration's focus on boosting domestic manufacturing under national security and economic resilience objectives.

India Looks to Diversify Export Markets

Even as uncertainty grows over future access to the US market, Indian pharmaceutical exporters are expanding their presence in other regions.

The recently implemented India-UK Comprehensive Economic and Trade Agreement (CETA) is expected to improve market access for Indian medicines in the United Kingdom through zero-duty provisions and enhanced regulatory cooperation.

Industry bodies believe stronger exports to Europe and other international markets could partially offset any long-term impact if higher US tariffs eventually come into force.

Uncertainty Remains

While Trump has outlined the proposed timeline, industry stakeholders are awaiting detailed implementation guidelines from the White House and US trade authorities. Clarifications are expected regarding the treatment of different categories of generic medicines, pharmaceutical ingredients, and manufacturers with existing US operations.

For now, the announcement provides pharmaceutical companies with a clear timeline—but also a significant strategic challenge. The next two years are likely to determine how global drug manufacturers, particularly those in India, adapt to one of the most consequential changes in US pharmaceutical trade policy.